Operating Income (Loss) of Liminatus Pharma, Inc. from 31 Mar 2024 to 30 Sep 2025

Taxonomy & unit: us-gaap: USD
Description: The net result for the period of deducting operating expenses from operating revenues.
Summary: Liminatus Pharma, Inc. quarterly Operating Income (Loss) in USD history and change rate from 31 Mar 2024 to 30 Sep 2025.
Liminatus Pharma, Inc. Operating Income (Loss) for the quarter ending 30 Sep 2025 was $701,170, a 29% decline year-over-year.
Source SEC data: View on sec.gov

Operating Income (Loss), Quarterly (USD)

Operating Income (Loss), YoY Quarterly Change (%)

Liminatus Pharma, Inc. Quarterly Operating Income (Loss) (USD)

Period	TTM Value	Value	YoY Chg	Change %	Start Date	End Date	Report	Filed	Fiscal Year	Fiscal Period
Q3 2025		$701,170	-$158,023	-29%	01 Jul 2025	30 Sep 2025	10-Q	14 Nov 2025	2025	Q3
Q2 2025		$1,118,211	-$208,993	-23%	01 Apr 2025	30 Jun 2025	10-Q	06 Oct 2025	2025	Q2
Q1 2025		$255^*	-$8		01 Jan 2025	31 Mar 2025	10-Q	02 Jun 2025	2025	Q1
Q3 2024		$543,147			01 Jul 2024	30 Sep 2024	10-Q	14 Nov 2025	2025	Q3
Q2 2024		$909,218			01 Apr 2024	30 Jun 2024	10-Q	06 Oct 2025	2025	Q2
Q1 2024		$247^*			01 Jan 2024	31 Mar 2024	10-Q	02 Jun 2025	2025	Q1

* An asterisk sign (*) next to the value indicates that the value is likely invalid.